Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AcruxASX:ACR EV-to-EBIT is 94.06 as of Jul. 18, 2026. The stock has 6 warning signs investors should review. Among 372 Biotechnology companies, Acrux ranks worse than 92.74% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acrux's Enterprise Value is A$7.53 Mil.
Acrux's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.08 Mil. Therefore, Acrux's EV-to-EBIT for today is 94.06.
The historical rank and industry rank for Acrux's EV-to-EBIT or its related term are showing as below:
ASX:ACR'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5.7 Med: -0.96 Max: 94.06
Current: 94.06
During the past 13 years, the highest EV-to-EBIT of Acrux was 94.06. The lowest was -5.70. And the median was -0.96.
ASX:ACR's EV-to-EBIT is ranked worse than 92.74% of 372
companies
in the Biotechnology industry
Industry Median: 13.35
vs ASX:ACR: 94.06
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Acrux's Enterprise Value for the quarter that ended in Dec. 2025 was A$7.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acrux's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrux EV-to-EBIT Related Terms
Acrux EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Acrux's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACR vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Acrux's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrux EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrux's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acrux's EV-to-EBIT falls into.
Acrux's current Enterprise Value is A$7.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acrux's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrux (ASX:ACR) has a EV-to-EBIT of 94.06 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acrux and its competitors. According to the industry distribution chart, Acrux ranks #345 out of 372 companies in the Biotechnology industry, placing it in the top 92.7%.
Is Acrux's EV-to-EBIT too high?
Acrux's current EV-to-EBIT is 94.06. The Biotechnology industry median EV-to-EBIT is 13.35. Acrux's value of 94.06 is 604.6% above this industry median. Based on the distribution chart, Acrux ranks #345 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Acrux's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrux ranks #345 out of 372 companies for EV-to-EBIT. This places Acrux in the lower half of its industry. The industry median EV-to-EBIT is 13.35. Acrux's value of 94.06 is 604.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrux's current EV-to-EBIT of 94.06 is 604.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acrux and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrux's current EV-to-EBIT is 94.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.01 — trading 60% below its estimated fair value. The current EV-to-EBIT is 94.06 and 604.6% above the Biotechnology industry median of 13.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Acrux (ASX:ACR), the current EV-to-EBIT is 94.06 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACR has been successfully added to your 
